Clinical Trial Update: Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update of HMBD-001, an anti-HER3 antibody, evaluating its use with or without chemotherapy in solid tumors with NRG1 fusions or HER3 muta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Pancreatic Cancer
• Solid Tumor

Drugs mentioned

• HMBD-001

Snippet

Sponsor: Hummingbird Bioscience | Conditions: Non-Small Cell Lung Cancer, Pancreatic Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING